Last reviewed 2026-04-22 · How we verify

CEV chemotherapy

CEV is a combination chemotherapy regimen that uses multiple cytotoxic agents to inhibit cancer cell division and induce apoptosis.

CEV is a combination chemotherapy regimen that uses multiple cytotoxic agents to inhibit cancer cell division and induce apoptosis. Used for Lymphomas and hematologic malignancies (specific indications vary by institution).

At a glance

Mechanism of action

CEV typically refers to a chemotherapy combination regimen, though the exact composition may vary by institution. Common interpretations include combinations of cyclophosphamide, etoposide, and vincristine or similar agents. These drugs work through different mechanisms—alkylating agents cross-link DNA, topoisomerase inhibitors prevent DNA repair, and vinca alkaloids disrupt microtubule formation—creating a multi-modal attack on rapidly dividing cancer cells.

Approved indications

• Lymphomas and hematologic malignancies (specific indications vary by institution)

Common side effects

• Myelosuppression
• Nausea and vomiting
• Alopecia
• Mucositis
• Infection risk

Key clinical trials

• Combination Chemotherapy and Cyclosporine Followed by Focal Therapy for Bilateral Retinoblastoma (PHASE2)
• Treatment of Tumors of the Choroid Plexus Epithelium (PHASE3)
• CEV With/Without Periocular Carboplatin Chemotherapy for Extraocular Retinoblastoma (PHASE4)
• Carboplatin Periocular Injection for Retinoblastoma (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• CEV chemotherapy CI brief — competitive landscape report
• CEV chemotherapy updates RSS · CI watch RSS
• Sun Yat-sen University portfolio CI